Kevin Fitzgerald - Jun 24, 2024 Form 4 Insider Report for ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Signature
By: Brett Budzinski, Attorney-in-Fact For: Kevin Fitzgerald
Stock symbol
ALNY
Transactions as of
Jun 24, 2024
Transactions value $
-$276,731
Form type
4
Date filed
6/26/2024, 04:26 PM
Previous filing
Mar 28, 2024
Next filing
Aug 14, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALNY Common Stock Award $0 +2.5K +19.39% $0.00 15.4K Jun 24, 2024 Direct F1
transaction ALNY Common Stock Sale -$9.98K -45 -0.29% $221.71 15.3K Jun 25, 2024 Direct F2, F3
transaction ALNY Common Stock Sale -$2.02K -9 -0.06% $224.17 15.3K Jun 25, 2024 Direct F2, F4
transaction ALNY Common Stock Sale -$2.93K -13 -0.08% $225.55 15.3K Jun 25, 2024 Direct F2, F5
transaction ALNY Common Stock Sale -$5.9K -26 -0.17% $226.82 15.3K Jun 25, 2024 Direct F2, F6
transaction ALNY Common Stock Sale -$21.9K -96 -0.63% $228.30 15.2K Jun 25, 2024 Direct F2, F7
transaction ALNY Common Stock Sale -$45.4K -198 -1.3% $229.06 15K Jun 25, 2024 Direct F2, F8
transaction ALNY Common Stock Sale -$52.2K -227 -1.51% $229.93 14.8K Jun 25, 2024 Direct F2, F9
transaction ALNY Common Stock Sale -$17.1K -74 -0.5% $231.59 14.7K Jun 25, 2024 Direct F2, F10
transaction ALNY Common Stock Sale -$37.4K -161 -1.1% $232.54 14.5K Jun 25, 2024 Direct F2, F11
transaction ALNY Common Stock Sale -$20.1K -86 -0.59% $233.53 14.4K Jun 25, 2024 Direct F2, F12
transaction ALNY Common Stock Sale -$32.4K -138 -0.96% $234.66 14.3K Jun 25, 2024 Direct F2, F13
transaction ALNY Common Stock Sale -$29.4K -125 -0.87% $235.19 14.2K Jun 25, 2024 Direct F2, F14
holding ALNY Common Stock 537 Jun 24, 2024 by Managed Account F15
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 23, 2022, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of one-third of the shares subject to the PSU based on the issuer publicly reporting of a positive, statistically significant result on a clinical outcomes endpoint from a Phase 3 clinical study in ATTR amyloidosis with cardiomyopathy, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on June 24, 2024.
F2 Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.
F3 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $221.37 to $222.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $223.92 to $224.43. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $224.99 to $225.98. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $226.45 to $227.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F7 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $227.72 to $228.71. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F8 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $228.75 to $229.72. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F9 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $229.76 to $230.70. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F10 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $230.92 to $231.78. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F11 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $231.97 to $232.97. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F12 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $233.00 to $234.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F13 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $234.06 to $235.04. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F14 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $235.10 to $235.73. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F15 Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.